Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence.

CONCLUSIONS: This study demonstrates that patient-specific ctDNA analysis can be a sensitive and specific approach for disease surveillance for breast cancer patients. More importantly, earlier detection of up to two years provides a possible window for therapeutic intervention.
PMID: 30992300 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 15, 2019 Category: Cancer & Oncology Authors: Coombes C, Page K, Salari R, Hastings RK, Armstrong AC, Ahmed S, Ali S, Cleator SJ, Kenny LM, Stebbing J, Rutherford MJ, Sethi H, Boydell AR, Swenerton R, Fernandez-Garcia D, Gleason K, Goddard KS, Guttery DS, Assaf Z, Wu HT, Natarajan P, Moore DA, Primro Tags: Clin Cancer Res Source Type: research